FENNEC PHARMACEUTICALS INC (FENC)

Company Profile

Fennec Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company is headquartered in Research Triangle Park, North Carolina and currently employs 36 full-time employees. The company went IPO on 2001-06-05. The firm sells its product through a field force, including regional pediatric oncology specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration (FDA) approved therapy indicates to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic and solid tumors. The company is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6.

Company Info

FENNEC PHARMACEUTICALS INC

PO Box 13628, 68 Tw Alexander Dr

RESEARCH TRIANGLE PARK NORTH CAROLINA 27709

P: 19196364530

CEO: Rostislav Raykov

Employees: 36

Website: https://fennecpharma.com/